Daily News Analysis

Issues with India’s Pharmaceutical sector

stylish_lining

Issues with India’s Pharmaceutical sector

Why in the News?

USFDA has issued a warning letter to a Gujarat-based Pharma manufacturing company citing serious violations of Good Manufacturing Practices (GMP).

India’s Pharma Sector:

  1. Indian pharma sector is set to achieve $130 billion by value, in the year 2030.
  2. The domestic Pharma companies are expected to report a steady revenue growth of 6-8 per cent in 2023-24.
  3. India is known as ‘the Pharmacy of the world’ as it is the world's third largest manufacturer of drugs by volume and second largest by value and known for its generic medicines and low-cost vaccines.
  4. India accounts for 60 percent of global vaccine production, contributing 40-70% of the WHO demand for DPT and BCG vaccines, and over 90% of the measles vaccine.
  5. The Exports of Pharmaceuticals have registered an increasing trend continuously for the past years.

 

 

 

 

Major segments of Indian Pharmaceutical Industry:

 

Generic drugs

      

 

 

Segments of Indian Pharmaceutical Industry

Research and Manufacturing

Biosimilars & Biologics

Over-the-Counter medicines

Bulk drugs

Vaccines

 

 

 

 

 

 

 

 

 

 

 

Challenges faced by the Pharma sector of India:

  1. Rising pressure from the US FDA:
    1. In 2018, USFDA inspections of Indian pharma manufacturing companies accounted for 14% of total FDA inspections across the world.
    2. Between 2013-18, 60 Drug good Manufacturing practices warning letters have been issued. This can potentially lead to,
      1. Negative impact on the share market value of Indian Pharma Companies.
      2. Hampering of the overall image of the pharma manufacturing quality.
  2. Government’s stringent control over the pricing of drugs turns out be a hurdle for the growth of innovative capabilities of Pharma companies, as the companies will restraint to invest in R&D activities as the assurance of getting the investment back through sale of drugs become bleak.
  3. Spurious drugs
    1. WHO reports that 35% of the world’s spurious drugs are produced in India, that are fake, counterfeit, or substandard.
    2. Gambia has made it mandatory for all Indian drugs to be tested before being exported to the African country since July 1, after Gambia reported death of dozens of children linked to consumption of cough syrup from India.
  4. Lack of skilled workforce:
    1. Gap between the theoretical degree studies and actual requirements of the industry, leading to a skill gap in spite of the fact that 4 lakh Pharma students graduate every year.
    2. This leads to sub-optimal utilisation and efficiency of the manpower.
    3. This also leads to Good Manufacturing Practices issues in the manufacturing processes.
  5. India’s high dependence on China for APIs:
    1. About 80% of India’s Active Pharmaceutical Ingredients’ (APIs), the raw materials used in the manufacture of medicines or formulations, requirements are fulfilled through imports from China.

Initiatives taken by India:

  1. PLI Scheme for Pharmaceuticals
    1. The scheme aims to enhance India’s manufacturing capabilities by increasing investment and production in the sector. This shall result in product diversification to high-value goods in the pharmaceutical sector.
    2. The scheme covers pharmaceutical goods under the following three categories-
      1. Category 1:

Biopharmaceuticals, Complex generic drugs, Patented drugs or drugs nearing patent expiry, Cell-based or gene therapy drugs, Orphan drugs, Special empty capsules, Complex excipients, Phyto-pharmaceuticals and other drugs as approved.

      1. Category 2:

Active Pharmaceutical Ingredients, Key Starting Materials and Drug Intermediates

      1. Category 3
        1. This includes Drugs not covered under Category 1 and Category 2.

Repurposed drugs, Auto-immune drugs, anti-cancer drugs, anti-diabetic drugs, anti-infective drugs, cardiovascular drugs, psychotropic drugs and anti-retroviral drugs, In-vitro diagnostic devices and other drugs not manufactured in India.

  1. Umbrella Scheme for Development of Pharmaceutical Industry
    1. A Central Sector Scheme namely ‘Strengthening of Pharmaceuticals Industry’ with three sub-schemes
      1. Assistance to Pharmaceutical Industry for Common Facilities (API-CF)
      2. Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS)
      3. Pharmaceutical & Medical Devices Promotion and Development Scheme (PMPDS)
    2. The scheme intends to increase the efficiency and competitiveness of domestic pharmaceutical and MedTech industry in the global market.
    3. Also, to ensure accessibility, availability and affordability of quality pharmaceuticals and medical devices for mass consumption.
  2. Promotion of Bulk Drug Parks scheme
    1. Aims for creation of world class common infrastructure facilities to bulk drug units located in the parks.
    2. The Bulk Drug parks can
      1. bring down the manufacturing cost
      2. Increase competitiveness of the domestic bulk drug industry
      3. Minimize country’s dependence on imports by providing a push to indigenous manufacturing and facilitate Indian bulk drug industry.
  3. Establishment of Pharma Bureau
    1. Provides facilitation to investors and resolves issues of inter-departmental coordination in the Pharmaceutical and Medical Device sector.
    2. It also policy support to Department of Pharmaceuticals for framing incentive schemes for the industry.

Collegium System of Judicial Appointments in India

The Collegium system refers to India's judicial process for appointing and transferring judges to the Supreme Court and High Courts. While the system plays a crucial role in maintaining judici
Share It

Sea-Level Rise

Coral micro-atolls are essential natural recorders of sea-level rise (SLR), offering valuable insights into past and present oceanic changes. These disk-shaped coral colonies provide a unique meth
Share It

India’s Strategy in the Indian Ocean

Why the Indian Ocean Matters: Strategic Importance: The Indian Ocean is the third-largest ocean in the world, hosting 1/3rd of the global population and acting as a crucial maritime trade
Share It

ASEAN Centrality

Why in the News? ASEAN’s central role in the Indo-Pacific is increasingly under strain due to rising great-power rivalry, shifting global trade dynamics, and the evolving regional order.
Share It

2025 SCO Summit in Tianjin

The 25th Shanghai Cooperation Organization (SCO) Summit held in Tianjin, China in 2025 brought together the heads of state of member countries to address a broad spectrum of issues, including secu
Share It

India’s Carbon Emissions Trading System

The Ministry of Environment, Forest and Climate Change (MoEFCC) has made a significant stride in India’s climate strategy by setting up the National Designated Authority (NDA) to implement a
Share It

Jan Vishwas (Amendment of Provisions) Bill, 2025

The Jan Vishwas (Amendment of Provisions) Bill, 2025 was introduced in the Lok Sabha to amend various provisions across several central acts with the goal of decriminalizing offences and promoting
Share It

Fair and Representative Global Order

India’s External Affairs Minister recently called for a fair and representative global order during the BIMSTEC Traditional Music Festival. The statement highlights the growing need for reforms
Share It

India's First EMI-Based Credit Card

Recently, Unity Small Finance Bank and BharatPe launched India's first EMI-driven credit card on the RuPay network. This innovative product allows users to pay for their purchases in full or c
Share It

Civil Society Organizations (CSOs)

Why in News? Civil Society Organizations (CSOs) have gained prominence for their vital role in promoting collective action, protecting rights, and filling gaps in governance. They serve as cata
Share It

Newsletter Subscription


ACQ IAS
ACQ IAS